FDA approves new lung cancer diagnostic tool, intraveneous opioid

Aug 10, 2020 - 03:00 PM
FDA product update

The Food and Drug Administration Friday the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

鈥淚n addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,鈥 said Tim Stenzel, M.D., director of FDA鈥檚 Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
FDA announces recall for certain IV bags
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride鈥
Headline
Recall issued for aspiration system by Q鈥橝pel Medical
The Food and Drug Administration has identified a Class I recall of Q鈥橝pel Medical 072 Aspiration System after the company submitted three device event reports鈥
Headline
FDA issues alerts on certain catheters produced by BD, Conavi
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue鈥
Headline
AHA launches online collaborative focused on quality improvement
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at鈥
Headline
AHA webpage highlights how hospitals and health systems integrate patient safety
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are鈥
Headline
FDA recalls Medtronic Aortic Root Cannulas聽
The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of unexpected loose material in the male luer鈥